Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF‑κB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling

Liu,Xiaodong; Tian,Shuo; Liu,Mei; Jian,Lingyan; Zhao,Limei

doi:10.3892/ijmm.2016.2700

Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF‑κB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling

Authors:
- Xiaodong Liu
- Shuo Tian
- Mei Liu
- Lingyan Jian
- Limei Zhao
View Affiliations

Affiliations: Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P.R. China, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Published online on: August 5, 2016 https://doi.org/10.3892/ijmm.2016.2700
Pages: 1250-1256

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The anticancer effects of the natural flavonoid, wogonin, have been reported. However, its molecular mechanisms of action have not yet been fully explored. In the present study, we aimed to examine the molecular mechanisms of action of wogonin and its effects on the biological behavior of the HepG2 and Bel7402 hepatocellular carcinoma (HCC) cell lines. We also examined the effects of wogonin on nuclear factor-κB (NF-κB)/Bcl-2 and epidermal growth factor receptor (EGFR) signaling, as well as on downstream pathways of EGFR, namely extracellular signal-regulated kinase (ERK)/AKT signaling. We found that treatment with wogonin inhibited the proliferation and invasion, and induced the apoptosis of the HepG2 and Bel7402 cells. In addition, treatment with wogonin decreased cyclin D1, cyclin E, CDK4/6, Bcl-2 and matrix metalloproteinase 2 (MMP2) expression, and promoted the cleavage of caspase-3 and caspase-9 in a concentration-dependent manner. Further experiments revealed that wogonin inhibited NF-κB/Bcl-2 signaling by decreasing the IκB and p65 phosphorylation levels. Wogonin also inhibited the activation of the EGFR (Tyr845) signaling pathway, and that of downstream pathways of EGFR, namely ERK/AKT/MMP2 signaling. The depletion of EGFR by siRNA partly abolished the inhibitory effects of wogonin on cyclin D1, MMP2 expression. On the whole, our our findings demonstrate that wogonin effectively suppresses the proliferation, invasion and survival of HCC cells through the modulation of the NF-κB and EGFR signaling pathways.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ye H and Liu W: Connectivity-based risk score for hepatocellular carcinoma prognosis. Hepatology. 58:1191–1192. 2013. View Article : Google Scholar : PubMed/NCBI
3	Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, et al: Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 56:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI
4	Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, et al: Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 49:491–503. 2009. View Article : Google Scholar
5	Ueng YF, Shyu CC, Lin YL, Park SS, Liao JF and Chen CF: Effects of baicalein and wogonin on drug-metabolizing enzymes in C57BL/6J mice. Life Sci. 67:2189–2200. 2000. View Article : Google Scholar : PubMed/NCBI
6	Wakabayashi I and Yasui K: Wogonin inhibits inducible prostaglandin E(2) production in macrophages. Eur J Pharmacol. 406:477–481. 2000. View Article : Google Scholar : PubMed/NCBI
7	Lin SJ, Tseng HH, Wen KC and Suen TT: Determination of gentiopicroside, mangiferin, palmatine, berberine, baicalin, wogonin and glycyrrhizin in the traditional Chinese medicinal preparation sann-joong-kuey-jian-tang by high-performance liquid chromatography. J Chromatogr A. 730:17–23. 1996. View Article : Google Scholar : PubMed/NCBI
8	Lin CC and Shieh DE: The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med. 24:31–36. 1996. View Article : Google Scholar : PubMed/NCBI
9	Chen LG, Hung LY, Tsai KW, Pan YS, Tsai YD, Li YZ and Liu YW: Wogonin, a bioactive flavonoid in herbal tea, inhibits inflammatory cyclooxygenase-2 gene expression in human lung epithelial cancer cells. Mol Nutr Food Res. 52:1349–1357. 2008. View Article : Google Scholar : PubMed/NCBI
10	Lee E, Enomoto R, Suzuki C, Ohno M, Ohashi T, Miyauchi A, Tanimoto E, Maeda K, Hirano H, Yokoi T and Sugahara C: Wogonin, a plant flavone, potentiates etoposide-induced apoptosis in cancer cells. Ann NY Acad Sci. 1095:521–526. 2007. View Article : Google Scholar : PubMed/NCBI
11	Himeji M, Ohtsuki T, Fukazawa H, Tanaka M, Yazaki S, Ui S, Nishio K, Yamamoto H, Tasaka K and Mimura A: Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett. 245:269–274. 2007. View Article : Google Scholar
12	He F, Wang Q, Zheng XL, Yan JQ, Yang L, Sun H, Hu LN, Lin Y and Wang X: Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species. Oncol Rep. 28:601–605. 2012.PubMed/NCBI
13	Huang KF, Zhang GD, Huang YQ and Diao Y: Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway. Int Immunopharmacol. 12:334–341. 2012. View Article : Google Scholar
14	He L, Lu N, Dai Q, Zhao Y, Zhao L, Wang H, Li Z, You Q and Guo Q: Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 312:36–47. 2013. View Article : Google Scholar : PubMed/NCBI
15	Saif MW: Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs. 19:357–369. 2010. View Article : Google Scholar : PubMed/NCBI
16	Navolanic PM, Steelman LS and McCubrey JA: EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol. 22:237–252. 2003.PubMed/NCBI
17	Lee DH, Szczepanski MJ and Lee YJ: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem. 106:1113–1122. 2009. View Article : Google Scholar : PubMed/NCBI
18	Raufman JP, Shant J, Guo CY, Roy S and Cheng K: Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. J Cell Physiol. 215:538–549. 2008. View Article : Google Scholar
19	Qian L, Liu Y, Xu Y, Ji W, Wu Q, Liu Y, Gao Q and Su C: Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. Cancer Lett. 368:126–134. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhao X, Ning Q, Sun X and Tian D: Pokemon reduces Bcl-2 expression through NF-κ Bp65: A possible mechanism of hepatocellular carcinoma. Asian Pac J Trop Med. 4:492–497. 2011. View Article : Google Scholar : PubMed/NCBI
21	Jia XF, Li J, Zhao HB, Liu J and Liu JJ: Correlation of EGFR gene amplification with invasion and metastasis of non-small cell lung cancer. Genet Mol Res. 14:11006–11012. 2015. View Article : Google Scholar : PubMed/NCBI
22	Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ and Gil-Henn H: An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res. 71:1730–1741. 2011. View Article : Google Scholar : PubMed/NCBI
23	Gong C, Zhang J, Zhang L, Wang Y, Ma H, Wu W, Cui J, Wang Y and Ren Z: Dynamin2 downregulation delays EGFR endocytic trafficking and promotes EGFR signaling and invasion in hepatocellular carcinoma. Am J Cancer Res. 5:702–713. 2015.PubMed/NCBI
24	Wang YP, Huang LY, Sun WM, Zhang ZZ, Fang JZ, Wei BF, Wu BH and Han ZG: Insulin receptor tyrosine kinase substrate activates EGFR/ERK signalling pathway and promotes cell proliferation of hepatocellular carcinoma. Cancer Lett. 337:96–106. 2013. View Article : Google Scholar : PubMed/NCBI
25	Alam S, Pal A, Kumar R, Dwivedi PD, Das M and Ansari KM: EGFR-mediated Akt and MAPKs signal pathways play a crucial role in patulin-induced cell proliferation in primary murine keratinocytes via modulation of Cyclin D1 and COX-2 expression. Mol Carcinog. 53:988–998. 2014.
26	Fiano V, Ghimenti C, Imarisio S, Silengo L and Schiffer D: PAkt, cyclin D1 and p27/Kip.1 in glioblastomas with and without EGFR amplification and PTEN mutation. Anticancer Res. 24:2643–2647. 2004.PubMed/NCBI
27	Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC and Galmiche A: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer. 131:2961–2969. 2012. View Article : Google Scholar : PubMed/NCBI
28	Kannangai R, Sahin F and Torbenson MS: EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol. 19:1456–1461. 2006.PubMed/NCBI
29	Bae GY, Choi SJ, Lee JS, Jo J, Lee J, Kim J and Cha HJ: Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget. 4:2512–2522. 2013. View Article : Google Scholar : PubMed/NCBI
30	Dong QZ, Wang Y, Tang ZP, Fu L, Li QC, Wang ED and Wang EH: Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 182:954–964. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kim H and Lim HY: Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. J Korean Med Sci. 26:1563–1568. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ling Y, Yang X, Li W, Li Z, Yang L, Qiu T, Guo L, Dong L, Li L, Ying J and Lin D: Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer. Oncotarget. July 13–2016.Epub ahead of print. View Article : Google Scholar
33	Shan L, Wang Z, Guo L, Sun H, Qiu T, Ling Y, Li W, Li L, Liu X and Zheng B: Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer. 89:337–342. 2015. View Article : Google Scholar : PubMed/NCBI
34	Nose N, Uramoto H, Iwata T, Hanagiri T and Yasumoto K: Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer. 71:350–355. 2011. View Article : Google Scholar
35	Chen GG, Liang NC, Lee JF, Chan UP, Wang SH, Leung BC and Leung KL: Over-expression of Bcl-2 against Pteris semipinnata L-induced apoptosis of human colon cancer cells via a NF-kappa B-related pathway. Apoptosis. 9:619–627. 2004. View Article : Google Scholar : PubMed/NCBI
36	Kurland JF, Voehringer DW and Meyn RE: The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis. J Biol Chem. 278:32465–32470. 2003. View Article : Google Scholar : PubMed/NCBI
37	Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM, Brisbay S and McDonnell TJ: Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res. 237:101–109. 1997. View Article : Google Scholar
38	Cheng JC, Chou CH, Kuo ML and Hsieh CY: Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene. 25:7009–7018. 2006. View Article : Google Scholar : PubMed/NCBI
39	Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, Lang J, Hung MC and Lin X: CARMA3 is crucial for EGFR-Induced activation of NF-kappaB and tumor progression. Cancer Res. 71:2183–2192. 2011. View Article : Google Scholar : PubMed/NCBI